Cargando…

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

OBJECTIVE: It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bansback, Nick, Curtis, Jeffrey R., Huang, Jie, He, Zeling, Evans, Michael, Johansson, Tracy, Michaud, Kaleb, Schmajuk, Gabriela, Liao, Katherine P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011419/ https://www.ncbi.nlm.nih.gov/pubmed/32043831 http://dx.doi.org/10.1002/acr2.11106

Ejemplares similares

Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry
por: Li, Jing, et al.
Publicado: (2021)

Evaluating the Use of Glucocorticoids Among Belimumab‐Treated Patients With Systemic Lupus Erythematosus in Real‐World Settings Using the Rheumatology Informatics System for Effectiveness Registry
por: Hammam, Nevin, et al.
Publicado: (2022)

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Biosimilars in rheumatology: understanding the rigor of their development
por: Goel, Niti, et al.
Publicado: (2017)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Biosimilars in rheumatology: what the clinician should know
por: Castañeda-Hernández, Gilberto, et al.
Publicado: (2015)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018)

The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study
por: Hammam, Nevin, et al.
Publicado: (2021)

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
por: Manders, Sofie HM, et al.
Publicado: (2015)

Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm
por: Schulze-Koops, Hendrik, et al.
Publicado: (2017)

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries
por: El Zorkany, Bassel, et al.
Publicado: (2018)

Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic
por: Bays, Alison, et al.
Publicado: (2016)

Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study
por: Michelsen, Brigitte, et al.
Publicado: (2022)

Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study
por: Chew, Caitlin, et al.
Publicado: (2021)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
por: Al Ani, Nizar Abdulateef, et al.
Publicado: (2018)

The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
por: Kravvariti, Evrydiki, et al.
Publicado: (2019)

Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data
por: McClean, Alison R., et al.
Publicado: (2022)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Probiotic Use and Psoriatic Arthritis Disease Activity
por: Grinnell, Madison, et al.
Publicado: (2020)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis
por: Grabner, Michael, et al.
Publicado: (2017)

2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists
por: Patrikos, Dimos, et al.
Publicado: (2019)

Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey
por: Castañeda‐Hernández, Gilberto, et al.
Publicado: (2019)

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
por: Di Giuseppe, Daniela, et al.
Publicado: (2021)

Association between self-reported race and ethnicity and myositis-specific autoantibodies in a diverse cohort of patients with inflammatory myopathy
por: Beam, Michael J., et al.
Publicado: (2023)

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
por: Cohen, Stanley, et al.
Publicado: (2022)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

An Instrument for Measuring Critical Appraisal Self‐Efficacy in Rheumatology Trainees
por: Aizer, Juliet, et al.
Publicado: (2022)

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
por: Taylor, Peter C., et al.
Publicado: (2023)

The untapped potential of Instagram to facilitate rheumatology academia
por: Bhatia, Ansh, et al.
Publicado: (2021)

Rapid Adoption of Telemedicine in Rheumatology Care During the COVID‐19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees
por: Yeoh, Su‐Ann, et al.
Publicado: (2021)

Evaluating imbalances of adverse events during biosimilar development
por: Vana, Alicia M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h0g4qcpgo23mjvkl65tr1i3hqo